Investment and funding

• To 2014 - Antikor Biopharma Limited was established in mid-2014 following the restructuring of PhotoBiotics Limited. The new Company retains the same ownership structure and constitution. To date the Company has been funded by business angels and initially (as Photobiotics) by Imperial Innovations Ltd.
• 2017 - Antikor was successful in securing a number of non dilutive grants from the EU and Innovate-UK. In 2017, the Company was awarded a large grant from Innovate UK to develop its first commercial product for gastric cancer.
• 2019 - Antikor were awarded an Innovate-UK Smart grant to further develop its linker technology to incorporate into its FDC platform. At the end of July, 2019, Antikor completed a $3.1 million investment and partnering deal with Essex Bio-Technology PLC. This strategic alliance gives Antikor a strong foundation to develop its technology and products and gives Essex Bio-Technology access to Antikor's innovative platform and future products for gastric and other solid tumours.
• 2022 - Antikor secured another large Innovate-UK grant to further develop its gastric cancer FDC supplemented with ~$2.2 million investment from existing shareholders led by Essex Bio-Technology. This funding funded the IND-enabling tumour cure efficacy studies and pilot, non-GLP safety studies in advanced, regulatory-required pre-clinical models.

Antikor’s business model, its research collaborations and ability to leverage the expertise and facilities at both Stevenage BioScience Catalyst and Imperial College, make it a lean, flexible and efficient organisation – and an exciting merger or trade sale opportunity, which will provide an attractive exit for investors.

Following on from its recent strategic alliance with Essex Bio-technology, Antikor is preparing for a Series A funding round, with a target of raising ~$15 million for clinical development of its products providing investors with a signficant return. If you are interested in the investment opportunities described here, please contact us to discuss your interest.